Oxford BioMedica benefits from TroVax results

Oxford BioMedica shares were boosted by the news that its first mid-stage trial of TroVax produced encouraging results for prostate cancer. Disease stabilization in patients currently ranges from two to 10 months. And anti-tumor immune response correlated with the clinical benefit, researchers say. TroVax is Oxford BioMedica's lead cancer immunotherapy product, which is being developed in collaboration with Sanofi-Aventis. The Phase II data were presented by the clinical investigators from the Methodist Hospital in Houston, Texas.

- and check out the press release
- read the report from Hemscott

Related Articles:
Is Sanofi preparing a bid for Oxford BioMedica? Report
Sanofi inks $690M pact for cancer vaccine. Report
Oxford BioMedica says licensing talks heating up. Report
Oxford BioMedica touts mid-stage TroVax trial data. Report

Suggested Articles

Eleusis researchers discovered that structural characteristics of the 2C-H class of psychedelics help to control asthma without behavioral effects.

Paragon Biosciences has hired Kerensa Jimenez as the new CEO of its capital markets group Paragon Health Capital.

Regeneron has taken a step closer to getting a green light for its experimental high cholesterol drug as the FDA allows a swift review of evicanumab.